Company / FCF Margin
Krystal Biotech, Inc. FCF Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
48.5%
FY2025
5-year range
-198.4% / 48.5%
FY2023-FY2025
Trend
+18.4%
vs FY2024
Sector context
#3 of 134
Health Care
What the data says
Among 134 Health Care companies, Krystal Biotech, Inc. is in the top 2% for fcf margin. Improved from -198.4% to 48.5% over the past 2 years.
Based on SEC 10-K filings.
48.5% in FY2025. Ranks 3rd among 134 companies in Health Care.
Improved from -198.4% to 48.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 2% in Health CareTop 2% of 134This company 48.5% Sector average -637.8%
▼
+107.6% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 18.4% year-over-year.
- Currently 686.3pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 48.5% | +18.4% |
| FY2024 | 41.0% | +120.7% |
| FY2023 | -198.4% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026